Thomas F. Widmann
Directeur/Membre du Conseil chez New York Philharmonic
Profil
Thomas F.
Widmann is the founder of Actelion Ltd.
founded in 1999.
He is currently the Director at New York Philharmonic.
His former positions include Chairman-Supervisory Board at Immatics Biotechnologies GmbH from 2004 to 2009, Independent Director at Cancer Genetics, Inc. from 2017 to 2019, Director-Supervisory Board at Trigen Holdings AG in 2009, Director at Symetis SA, and General Partner at Wellington Partners GmbH from 2003 to 2017.
Dr. Widmann's education includes an undergraduate degree from Ruprecht-Karls-Universität Heidelberg and a doctorate from the University of Geneva.
Postes actifs de Thomas F. Widmann
| Sociétés | Poste | Début |
|---|---|---|
New York Philharmonic
 New York Philharmonic Movies/EntertainmentConsumer Services New York Philharmonic provides live theatrical presentations. The company was founded in 1842 and is headquartered in New York, NY. | Directeur/Membre du Conseil | - |
Anciens postes connus de Thomas F. Widmann
| Sociétés | Poste | Fin |
|---|---|---|
| CANCER GENETICS, INC. | Directeur/Membre du Conseil | 31/05/2019 |
Immatics Biotechnologies GmbH
 Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany. | Président | 12/11/2012 |
Trigen Holdings AG
 Trigen Holdings AG Miscellaneous Commercial ServicesCommercial Services Trigen Holdings AG develops drugs focusing on thrombosis and vascular dysfunction. Its product pipeline includes clinical stage candidates, TGN 255, TGN 167 and PR-15. The company has offices in London. Trigen Holdings was founded in 2005 and is headquartered in Martinsried, Germany. | Directeur/Membre du Conseil | 15/12/2009 |
| ACTELION | Fondateur | 01/01/2003 |
| SYMETIS SA | Directeur/Membre du Conseil | - |
Formation de Thomas F. Widmann
| Ruprecht-Karls-Universität Heidelberg | Undergraduate Degree |
| University of Geneva | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 7 |
|---|---|
Trigen Holdings AG
Trigen Holdings AG Miscellaneous Commercial ServicesCommercial Services Trigen Holdings AG develops drugs focusing on thrombosis and vascular dysfunction. Its product pipeline includes clinical stage candidates, TGN 255, TGN 167 and PR-15. The company has offices in London. Trigen Holdings was founded in 2005 and is headquartered in Martinsried, Germany. | Commercial Services |
Immatics Biotechnologies GmbH
Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany. | Health Technology |
Wellington Partners GmbH
 Wellington Partners GmbH Investment ManagersFinance Wellington Partners GmbH (Wellington Partners) is an independent venture capital firm founded in 1991 by Rolf Christof Dienst. The firm is headquartered in Munich, with offices in Zurich, London, and Palo Alto. | Finance |
Actelion Ltd.
 Actelion Ltd. Pharmaceuticals: MajorHealth Technology Actelion Ltd. develops, produces and markets pharmaceutical drugs. The firm engages in research, development, manufacturing, and distribution of pharmaceutical, biological, and diagnostic products. The company was founded by Jean-Paul Clozel, Martine Clozel, Walter Fischli, André J. Müller and Thomas Widmann on December 30, 1999 and is headquartered in Allschwil, Switzerland. | Health Technology |
Symetis SA
 Symetis SA BiotechnologyHealth Technology Symetis SA develops minimally invasive heart valve replacement devices. Its products include ACURATE TA and ACURATE neo. The company was founded by Simon P. Hoerstrup and Gregor Zünd on September 5, 2001 and is headquartered in Ecublens, Switzerland. | Health Technology |
New York Philharmonic
New York Philharmonic Movies/EntertainmentConsumer Services New York Philharmonic provides live theatrical presentations. The company was founded in 1842 and is headquartered in New York, NY. | Consumer Services |
Cancer Genetics, Inc.
 Cancer Genetics, Inc. Medical SpecialtiesHealth Technology Cancer Genetics, Inc. engages in the development, commercialization, and sale of molecular and biomarker-based tests and services. Through its Select One Clinical Trials program, the firm provides a range of clinical trial services for both oncology and non-oncology genetic testing such as bioinformatics, biomarker solutions, bio repository solutions, consulting, cytogenetic testing, nucleic acid extraction and purification, flow cytometry, Focus: NGS Panel, gene expression analyses, genotyping, and pharmacogenomics. The company was founded by Raju S. K. Chaganti on April 8, 1999 and is headquartered in Rutherford, NJ. | Health Technology |
